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Work over several decades has laid solid foundations for the
advancement of liver cell therapy. To date liver cell therapy in peo-
ple has taken the form of hepatocyte transplantation formetabolic
disorderswith a hepatic basis, and for acute or chronic liver failure.
Although clinical trials using various types of autologous cells have
been implemented to promote liver regeneration or reduce liver
ﬁbrosis, clear evidence of therapeutic beneﬁts have so far been
lacking. Cell types that have shown efﬁcacy in preclinical models
include hepatocytes, liver sinusoidal endothelial cells, mesenchy-
mal stem cells, endothelial progenitor cells, and macrophages.
However, positive results in animalmodels have not always trans-
lated through to successful clinical therapies and more realistic
preclinicalmodels need to be developed. Studies deﬁning the opti-
mal repopulation by transplanted cells, including routes of cell
transplantation, superior engraftment and proliferation of trans-
planted cells, as well as optimal immunosuppression regimens
are required. Tissue engineering approaches to transplant cells in
extrahepatic locations have also been proposed. The derivation
of hepatocytes from pluripotent or reprogramed cells raises hope
that donor organ and cell shortages could be overcome in the
future. Critical hurdles to be overcome include the production of
hepatocytes from pluripotent cells with equal functional capacity
to primary hepatocytes and long-termphenotypic stability in vivo.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Journal of Hepatology 20
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Orthotopic liver transplantation (OLT) is the standard of care for
people with end-stage liver disease and for certain liver-based
metabolic defects [1]. However, successful replacement of deﬁ-
cient liver functions by transplantation of healthy hepatocytes,
e.g., in animal models and people with Crigler-Najjar syndrome
due to UGT1 enzyme deﬁciency, familial hypercholesterolemia
due to low-density lipoprotein receptor (LDLR) deﬁciency, or
acute and chronic liver failure indicated that OLT could possibly
be avoided [2–6]. This general concept has been emphasized by
similar successes with auxiliary partial orthotopic liver trans-
plantation (APOLT) for enzymatic deﬁciency states or acute liver
failure [7]. In the latter case, discontinuation of immunosuppres-
sion when the native liver regenerates after APOLT may lead to
spontaneous rejection and atrophy of the allogeneic liver graft
[8,9] The clinical experience with APOLT gives credence to the
hypothesis that the relevant functional unit of the liver – ‘‘the
hepatocyte’’ could be used to correct discrete enzyme defects
and support metabolic functions for the failing liver after injury
whilst it regenerates. Similarly, successful correction of haemo-
philia by OLT, indicated that consideration of cell therapy will
be appropriate for other classes of diseases. In principle, cell
transplantation is far simpler than either OLT or APOLT, because
1) cells from a donor liver may be transplanted into multiple
recipients; 2) cell transplantation is simpler using cell
administration via intravascular catheters rather than complex
surgery; 3) if cryopreserved cells are used, therapies could be
undertaken in a prospective non-emergency setting; 4) cells
may even be transplanted repeatedly, the procedure can be con-
sidered ‘‘reversible’’ since the native liver is not removed; and 5)
the costs of transplanting cells should be considerably less than
that of organ transplantation.
Subsequent to the early demonstrations of whether trans-
planted cells may engraft and function in the liver and in a vari-
ety of extrahepatic sites [10], a large body of work in many small
and large animal models supported studies of the potential of
hepatocyte transplantation [11,12]. More recently, the therapeu-
tic value of other liver cell types was elucidated. For instance,
transplantation of liver sinusoidal endothelial cells (LSECs) cured
haemophilia A in mice after LSECs were found to be the major15 vol. 62 j S157–S169
Critical components of liver cell therapy and current barriers
Step 1.
Isolation, characterization
and storage of donor cells
Step 2.
Transplanted cell
engraftment
± gene transfer
Drug or other modifications
Major
barriers
• Inferior donor quality
• Low viability or number
• Freeze-thaw damage
• Transplanted cells do not proliferate in 
the liver
• Allografts are rejected
Most transplanted cells 
are cleared rapidly from 
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Hepatocytes
LSECOther cells 
(e.g., stem cell-derived)
Recipient pre- or 
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Transplanted cell
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Fig. 1. Depiction of critical components in liver cell therapy and barriers in various steps. The ﬁrst step in cell therapy requires isolation, characterization and storage of
suitable donor cells. These steps are restricted by donor organ shortages or their inferior quality, procedural limitations in isolating cells of high viability and large numbers,
as well as difﬁculties in cryopreservation of cells. The second critical step concerns engraftment of transplanted cells in the liver (or extrahepatic sites), which requires
overcoming of early transplanted cell clearances. Cells may be modiﬁed by gene transfer vectors, drugs or other ways for improving cell viability, engraftment and
proliferation. In the third and ﬁnal step, transplanted cells must survive over the long-term and also proliferate to the necessary extents for imparting therapeutic beneﬁts,
which may require conditioning of recipients either before or after cell transplantation, as well as development of suitable regimens for controlling allograft rejection.
Reviewsource of FVIII [13]. Applications of LSECs may extend to liver
repair since these cells have been shown to be critical for liver
regeneration in mice [14]. Pathophysiological processes that
could be altered during chronic liver injury and ﬁbrosis by the
cell transplantation approach have also gained interest [15]. In
some people with acute liver failure, cell transplantation has
been successful for bridging to OLT, whereas in other instances,
people with liver failure or enzymatic deﬁciency states had to
be treated with OLT because cell therapy proved unsuccessful
[6]. In part, this difﬁculty in achieving superior outcomes of cell
therapy has been related to immunosuppression following allo-
geneic cell transplants, since optimal regimens for inducing toler-
ance to transplanted liver cells are to be established.
In the setting of metabolic liver disease and hepatic injury, e.g.,
hereditary tyrosinemia type-1 or Wilson’s disease, animal studies
established that disease correction can be achieved because even
modest numbers of healthy transplanted hepatocytes can pro-
liferate and repopulate the liver [16,17]. This process of liver
repopulation has been shown in rodents to be accelerated by
recipient organ preconditioning [18]. By contrast, in the setting
of metabolic diseases where the native liver is unaffected and
remains totally healthy, as in Crigler-Najjar syndrome or familial
hypercholesterolemia, transplanted hepatocytes engraft but do
not proliferate in the liver because this is not physiologically
required. Therefore, in achieving therapeutic levels of repopulation
further manipulation is required by either: a) preconditioning of
the recipient’s liver using techniques such as DNA-adduct forming
chemicals, radiation, oxidative stress or by b) modiﬁcation ofS158 Journal of Hepatology 2015donor cells by altering liver growth or cell cycle controls, such that
transplanted cells receive survival and/or proliferation advantages
over native cells [18,19]. In this way, the concept of ‘‘liver trans-
plantation to cell factory’’ may be gained if one considers that suc-
cessive generations of daughter cellsmay emanate in the recipient
liver from transplanted hepatocytes, as was elegantly established
using serial hepatocyte transplants in the fumarylacetoacetate-
hydrolase-deﬁcient (FAH/) mouse model [20]. If these
concepts regarding liver repopulation are reduced to drug-based
approaches then barriers in transplanted cell engraftment and
proliferation will be overcome for more effective clinical trials.
For many reasons, the clinical application of liver cell therapy
has proceeded at a gradual pace in people compared to the suc-
cesses in preclinical animal studies. Some of the obstacles con-
cern limited availability of donor livers, difﬁculties in isolating
good-quality cells from often suboptimal donor livers, mechanis-
tic restrictions in cryopreserving human liver cells without losing
viability, low levels of engraftment and proliferation in trans-
planted liver cells, as well as the general lack of therapeutic bene-
ﬁts over the long-term due to allograft rejection (Fig. 1). Another
important point is that the animal models used often translate
poorly to the clinic. Liver damage may have accumulated over
decades in patients with severe distortion of liver architecture
and impairment of function. The models of liver injury developed
in mice and rats typically occur over days or weeks and are often
milder than the human diseases they seek to model. An impor-
tant message is that more realistic models of these liver injuries
are required.vol. 62 j S157–S169
Table 1. Potential clinical indications for liver cell therapy.⁄
A. Congenital disorders
• Alpha-1 antitrypsin deficiency*
• Crigler-Najjar syndrome type 1*
• Familial hypercholesterolemia*
• Congenital coagulation factor VII deficiency*
• Hemophilia A
• Glycogen storage disease type I*
• Infantile Refsum disease
• Maple syrup urine disease
• Neonatal hemochromatosis
• Urea cycle defects - ornithine transcarbamylase
 
carbamoylphosphate synthase type 1 deficiency; 
citrullinemia*
• Wilson’s disease
B. Acquired disorders
• Acute liver failure (multiple etiologies)*
• Fatty liver of pregnancy*
• Acute-on-chronic liver
(OTC) deficiency; arginosuccinate lyase deficiency;
 failure (multiple etiologies)*
• Progressive familial intrahepatic cholestasis type 2 (PFIC2)
⁄Indicates conditions treated by cell transplantation in people.
JOURNAL OF HEPATOLOGYKey Points 
• Liver cell therapy has extensive value for paediatric and 
adult populations with many enzyme deficiency states, 
metabolic diseases, coagulation disorders, as well as 
liver failure
• Much of the clinical literature is based upon case 
reports although some controlled studies have also 
been conducted
• Widespread applications of liver cell therapy have been 
constrained by donor organ shortages and limitations in 
transplanted cell engraftment and proliferation
 
• Utilization of stem cells offers hope for producing 
suitable liver cells of clinical utility although barriers 
include the production of cells with the necessary levels 
of differentiated function and karyotypic stability
• Approaches to regenerate liver or reducing liver fibrosis 
or promoting endogenous repair and regeneration are 
being developed and testedTable 2. Selected examples of animal models used in cell transplantation
studies.
Mechanisms in cell engraftment and proliferation
Dpp4-deficient F344 rats and Dpp4 knockout mice
Transgenic donor mice (HBV, human alpha-1 antitrypsin, beta-
galactosidase, alb-uPA, etc.)
Fumarylacetoacetate hydroxylase (FAH) knockout mice
Defects in hepatic detoxification
• FAH knockout mice (hereditary tyrosinemia, type-1)
• Gunn rat and MRP-2 knockout mice (Crigler-Najjar 
syndrome, type-1)
• Histidinemia mice (histidinemia)
• MSUD knockout mouse (Maple syrup urine disease) 
• Spf-ash mice (OTC deficiency)
Secretory protein deficiency
• Nagase analbuminaemic rat (hypoalbuminaemia)
• Hemophilia A mice
Diseases of receptor function 
• Watanabe heritable hyperlipidemic rabbit (familial 
hypercholesterolaemia)
• Apolipoprotein E knockout mouse (hypercholesterolemia)
Transport defects 
• TR- rat and Mdr2 knockout mouse (PFIC1)
• BSEP knockout mouse (PFIC2)
• Long-Evans Cinnamon rat and Atp7b knockout mouse 
(Wilson’s disease)
Acquired disorders
• Induced acute liver failure (hepatectomy, chemicals, drugs, 
viruses, physical methods)
• Chronic liver disease (CCl4, thiocetamide, acetyl-
aminofluorene, etc.)Major clinical indications and roles of cell therapy
The premise for early studies in people was based on transplant-
ing healthy cells to replace deﬁcient functions in acquired or
inborn errors of metabolism besides supporting the failing liver
(Table 1). Liver-based metabolic defects are usually secondary
to a missing enzyme with consequences secondary either to the
lack of a normally functioning protein or the upstream accumula-
tion of toxic substances due to impaired metabolism of a protein.
These diseases could be further classiﬁed into those with no
effects on the liver and those leading to liver injury and ﬁbro-
sis/cirrhosis. The rationale for hepatocyte transplantation in peo-
ple with these conditions came from animal studies showing that
healthy hepatocytes transplanted into hepatic or extrahepatic
sites possessed properties as follows (Table 2): 1) engraftment
and proliferation in the liver or other sites; 2) enzymatic activity
for detoxiﬁcation, e.g., bilirubin glucuronidation followed by the
biliary excretion of conjugated bilirubin in Gunn rats modelling
Crigler-Najjar syndrome; 3) release of secreted proteins, e.g.,
albumin synthesis and release in Nagase analbuminemic rats
(NAR); 4) receptor-mediated ligand uptake, e.g., LDLR-dependent
clearance of cholesterol in Watanabe heritable hyperlipidemic
cholesterolemic rabbits (WHHL); 5) ammonia-ﬁxation in rats
with portacaval shunts; and 6) improvements in mortality in rats
and rabbits with induced acute liver failure [21–24]. These
demonstrations were better understood after the important dis-
covery in rodents that hepatocytes transplanted into liver sinu-
soids enter liver parenchyma and integrate with adjacent native
hepatocytes along with the reconstitution of plasma membrane
structures permitting restoration of cell polarity and transport
or exchange functions (Fig. 2) [25–27].
Moreover, studies in rat showed that transplanted cells
retained position-speciﬁc and physiologically-regulated patterns
of gene expression, and exhibited lifetime survival with normal
liver growth controls in the absence of allograft rejectionJournal of Hepatology 2015 vol. 62 j S157–S169 S159
AGap junctions Bile canaliculi
B
Fig. 2. Integration of dipeptidyl peptidase IV (Dpp4)-positive adult hep-
atocytes in liver parenchyma of healthy Dpp4-negative rats. (A) Combined
staining for Dpp4 (red color, arrows) and hepatic connexin 32 (brown color,
arrowheads) showing sharing of gap junctions by adjacent transplanted and
native hepatocytes. (B) Reconstitution of bile canalicular networks in trans-
planted hepatocytes (Dpp4 staining, red color, arrows) and native hepatocytes
(ATPase staining, brown color, arrowheads). Modiﬁed from Gupta et al. Proc Natl
Acad Sci 1995.
Review[28,29]. These ﬁndings prompted numerous studies of liver cell
biology and stimulated clinical hepatocyte transplantation (listed
in Table 2). Although hepatocyte transplantation in animal stud-
ies has been shown to correct enzymatic, receptor, proteolytic or
transport defects in the setting of no liver injury and early in
disease processes, in conditions associated with progressive liver
injury, e.g., alpha-1 antitrypsin deﬁciency, Wilson’s disease, bil-
iary phospholipid excretion (Mdr2/3 deﬁciency) or progressive
familial intrahepatic cholestasis (BSEP deﬁciency) [18,30], realiz-
ing such gains in people with these conditions awaits further
advances as discussed below.
In an early human trial, autologous hepatocytes isolated from
resected liver were returned via intrasplenic injection in several
cirrhotic individuals but without clear clinical beneﬁts [31]. The
unique vascular and extracellular matrix architecture of the
spleen permits survival and proliferation of transplanted hep-
atocytes although studies in rat show that the majority (90%)
of transplanted cells enter instantaneously into the portal vein
and then liver sinusoids [32]. Similarly, after acute injury, the
liver can be seeded by transplanting cells into the portal vein.
On the other hand, attachment of hepatocytes to extracellular
matrix scaffolds can help in their engraftment in extrahepatic
sites, e.g., subcutaneous fat pads or peritoneal cavity as demon-
strated in the rat [24]. Therefore, it was possible to examine
major principles for supporting the failing liver, i.e., to under-
stand the role of reseeding the liver with healthy cells vs.
provision of metabolic support and paracrine factors from trans-
planted cells in liver regeneration. Whilst cell transplantation
improved outcomes in animals with induced liver failure, it
was also found in rat that besides intact cells, fragmented cells,
culture medium supernatant from cells, and transplantation of
even allogeneic or xenogeneic hepatocytes that were rapidly
cleared, were also capable of rescue in acute liver failure [33].
This raised the possibility that paracrine factors could be
important for cell therapy in liver failure, which recently gained
renewed attention.S160 Journal of Hepatology 2015The experience in single cases or uncontrolled trials of hep-
atocyte transplantation via spleen, portal vein or intraperitoneal
administration in several adults and children with acute liver fail-
ure has been mixed but with some notable successes, as deﬁned
by spontaneous recovery or bridging to OLT [6]. Of course, injec-
tion of cells into the portal venous system is made difﬁcult in
these patients by coagulopathy and associated portal hyperten-
sion, which presents the risk of systemic embolization or portal
vein thrombosis. Moreover, liver inﬂammation and injury could
be aggravated by ischemic injury produced by the arrival of
transplanted cells in liver sinusoids and activation of ischemic
events. Immunosuppression after the transplantation of allo-
geneic cells also adds the risk of sepsis in this vulnerable
population.
In preclinical rat studies, transplantation of healthy hep-
atocytes in the liver after acute toxic injury established that the
transplanted cells required several days before they could pro-
liferate and liver repopulation was very limited [34]. Therefore,
it was of interest when investigators used the peritoneal cavity
for transplanting freshly isolated, allogeneic fetal human hep-
atocytes in people with acute liver failure [35,36]. Of eight persons
with acute liver failure and hepatocyte transplantation in this
manner, four people recovered. In these studies hepatocytes were
transplanted without matrix support or anchorage, which would
have led to the rapid loss of transplanted cells, raising a question
about the mechanisms underlying the rescue. More recently, ani-
mal studies established ATM (ataxia telangiectasia mutant) gene
network-related molecular lesions in hepatocytes after drug-
induced acute liver failure, as another explanation of the failure
of liver regeneration [37]. These studies established that rescue
did not require reseeding of the liver with transplanted cells since
hepatocytes transplanted into the peritoneal cavity provided
metabolic support along with paracrine factors to advance liver
regeneration. Therefore, transplantation of hepatocytes with
matrix support offers a viable alternative approach for rescue in
acute liver failure as shown inmice [38]. This should be simpliﬁed
by the possibility of cryopreserving immobilized hepatocytes [39].
In ongoing studies, human hepatocytes encapsulated in alginate
beads (to avoid exchange of immunoglobulins and immunocytes
driving alloresponses but not of desirable proteins) were
intraperitoneal administered to several children with acute liver
failure. In vitro experiments showed that albumin and factor VII
were produced for at least 2 weeks or longer when microbeads
were cultured in ascites ﬂuid obtained from children in the post
liver-transplant period [40]. Of seven childrenwith acute liver fail-
ure, three avoided OLT after intraperitoneal transplantation of
alginate-encapsulated hepatocytes (Dhawan A, personal commu-
nication unpublished observations). These results offer mecha-
nisms for further cell therapy approaches for acute liver failure,
including studies with additional cells of therapeutic interest.
For cell therapy in the setting of advanced chronic liver dis-
ease or cirrhosis due to hepatitis, alcohol or unspeciﬁed injury,
one must take into account the depletion of parenchymal cells,
architectural distortions, vascular reorganization, inﬂammation
and excessive extracellular matrix deposition, and myoﬁbroblast
activation and proliferation. This distorted liver microenviron-
ment is naturally challenging for the engraftment and prolifera-
tion of transplanted cells. In preclinical studies in rats using
carbon tetrachloride-induced cirrhosis, transplanted hepatocytes
engrafted but did not proliferate signiﬁcantly in ﬁbrotic liver after
withdrawal of the injurious agent and no beneﬁts were noted invol. 62 j S157–S169
Catheter through
umbilical vein 
(in newborn)
Intraportal infusion
(percutaneous)
Hickman line
in inferior 
mesenteric vein
Main criteria
•   Fresh or cryopreserved hepatocytes
•   Cell viability should be >60%
•   ABO blood group compatible
•   Up to 109 cells per infusion
•   Portal pressure monitoring
•   Repeated up to 5-10% liver mass
•   Immunosuppression-tacrolimus and steroids
Fig. 3. Routes for delivering cells into the portal venous system and major
criteria for donor cell usage in the clinical setting. The radiographic image in
the box indicates hepatocytes being infused via the umbilical vein into the liver of
a new-born with urea cycle deﬁciency disorder. From Dhawan, Transplantation.
Used with permission.
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outcomes related to hepatic function or liver ﬁbrosis [41]. By con-
trast, transplantation of hepatocytes into the spleen of rats with
end-stage liver failure was found to prolong survival [42]. There
have been a number of clinical studies seeking to transplant adult
hepatocytes into patients with liver cirrhosis [15]. These studies
have attempted various ways to transplant hepatocytes, includ-
ing directly into the liver or via spleen as well as in the peritoneal
cavity. Transplantation of cells into the liver in this situation is
obviously difﬁcult because of coagulopathy and portosystemic
collaterals with risks of serious cardiopulmonary complications.
However, despite the possibility that selected parameters may
have improved in some cases, in general these studies have not
met with great success. In the absence of disease processes that
may be modiﬁed by transplanted hepatocytes, e.g., mobilization
of copper in Wilson’s disease, removal of toxins in progressive
familial intrahepatic cholestasis, or replenishment of disease-re-
sistant cells in chronic hepatitis, underlying issues of portal
hypertension, excess extracellular matrix deposition and vascular
distortions may not improve. An alternative approach recently
suggested, following positive results in mice, the seeding of hep-
atic cells into the lymphatics [43]. Whether this interesting
approach is translatable in the setting of human cirrhosis remains
to be seen.
An alternative cell therapy approach to liver cirrhosis is the
transplantation of cells that may stimulate endogenous regenera-
tion or decrease ﬁbrosis (see Table 4 for different types of poten-
tial cell therapy depending upon disease scenario). For instance,
Thomas et al. studied the intraportal injection of bone marrow-
derived macrophages for liver ﬁbrosis and found signiﬁcant
reduction in liver scarring and improvements in regeneration
and metabolic function in mice [44]. Macrophages directly acti-
vate the liver’s ductular response via Tweak/FN14 signalling
[45] and stimulate such cells towards an hepatocyte phenotype
via Wnt signalling [46]. Injected macrophages have strong para-
crine and chemotactic effects which amplify their beneﬁt but
only survive for a short time in the liver, which may limit efﬁcacy
without repeated administration. Nakamura et al. used endothe-
lial progenitor cells (EPCs) in rat models of liver ﬁbrosis and
found them to be anti-ﬁbrotic and also capable of stimulating
liver regeneration [47]. Similarly, DeLeve and colleagues estab-
lished that bone marrow-derived liver sinusoidal endothelial pro-
genitor cells could be targeted to the liver with improvement in
liver inﬂammation and hepatic injury in rats [48].
Terai et al. utilized autologous mononuclear cells from
patients with advanced liver disease by bone marrow aspiration
[49]. The cells were puriﬁed prior to re-infusion via the periph-
eral vein. A pilot study showed encouraging preliminary results
where liver function and histological parameters of liver
regeneration improved following cell therapy. The peripheral
administration of autologous mesenchymal stem cells (MSCs)
have been tested in a randomized, placebo-controlled trial in cir-
rhosis but no beneﬁcial effect was seen, indeed 3 out of 15
patients that received the MSCs died in the ﬁrst 5 months follow-
ing cell administration compared to zero from 12 in the control
group [50]. The clinical studies of various autologous cells for
liver disease have been systematically reviewed by Moore et al.
and to date no convincing beneﬁt has been noted in adequately
powered randomized controlled studies [51]. However it is worth
noting that due to the early state of the ‘‘therapies’’ tested many
studies were small uncontrolled studies that did not allow a mea-
sure of efﬁcacy.Journal of Hepatology 2015The issues of cell delivery
The relatively superﬁcial location of the liver and access through
a variety of modalities, including percutaneous, intravascular
through either portal vein or hepatic artery, as well as vessels
upstream of the portal vein offer multiple ways to deliver cells
(Fig. 3). However, studies in rat have established that for trans-
planted cells to integrate in the liver parenchyma, the most effec-
tive approach is to deliver cells into hepatic sinusoids [52].
Injecting cells directly into the liver parenchyma has the risk of
inadvertent entry into hepatic venous outﬂow tract and entry
of cells into pulmonary capillaries with embolic consequences.
Injection of cells into the hepatic or splenic artery is technically
convenient but this may lead to organ infarcts, again due to
embolic processes [53]. Under high-ﬂow conditions of the arterial
circulation transplanted cells may be destroyed rapidly by shear
forces, which is equally applicable to the pulmonary, hepatic and
splenic arterial beds. By contrast, transplantation of hepatocytes
under low-ﬂow conditions coupled with access to additional cell
attachment factors and extracellular matrix components, as in
the liver or spleen sinusoids, has been most effective for hep-
atocyte delivery, persistence and engraftment. In the case of the
spleen in rat, most (90%) of the cells instantaneously migrate into
the portal vein followed by redistribution equally to all liver lobes
in accordance with blood ﬂow and liver volumes [32]. The num-
ber of cells that may be safely accommodated in the sinusoids is
substantial and approaches 5–10% of the total number of
parenchymal cells in the healthy rat liver [54]. Moreover, studies
in rodents have shown that cells may be transplanted repeatedlyvol. 62 j S157–S169 S161
Review
without deleterious consequences on hepatic vasculature or liver
sinusoids [55].
The initial transplanted cell distributions has been examined
in rodents using radiolabeled or genetically-marked reporter liver
cells, which provide additional methods for non-invasive tracking
of the initial fate of transplanted cells [27,32]. A clinically rele-
vant ﬁnding is that cell transplantation results in transient portal
hypertension, which is due to transplanted cell size-dependent
occlusions in the periportal vascular complex, followed by the
restoration of blood ﬂow through the opening of alternative vas-
cular channels as well as by the entry of transplanted cells into
the liver parenchymal structure over several hours [56].
However, the transplantation of cells in the presence of pre-
existing portal hypertension and chronic liver disease may lead
to excessive translocation of cells into lungs through portosys-
temic collaterals or channels with cardiovascular complications.
These may be related to the dosages of cells administered.
Therefore, clinical trial design needs to incorporate mechanisms
for the successful initial delivery of cells to liver sinusoids.Engraftment of transplanted cells including tracking and
monitoring of the delivered cells
After delivery of transplanted cells to liver sinusoids, several
steps follow before cells are fully integrated in the liver parench-
yma (hepatocytes) or in appropriate niches of the liver structure
(LSEC and other cell types) [13,56,57]. Studies in rats have shown
that the initial series of events are driven by the mechanical pro-
cess by which cells enter vascular spaces beyond the portal areas,
which is dependent upon the size of cells and the diameter of
hepatic sinusoids [54]. The larger the size of cells, the more proxi-
mal will these be to portal areas, and the smaller the size of cells,
the more distal in the liver lobule will these be in relationship to
portal areas. This essential size-structure relationship drives the
nature of cell-cell adhesions, as well as the extent of vaso-occlu-
sive processes that may be initiated by cell transplantation.
Rodent studies have shown that subsequent cell-cell signalling
events are important. The ischemic injury rapidly activates neu-
trophils, Kupffer cells, LSECs and hepatic stellate cells [58,59].
The initial engraftment processes where vascular responses
involve release of locally-acting vasoactive molecules, such as
NO and prostacyclins, complement, platelet-related thrombo-
genic substances, endothelin, cyclooxygenases, cytokines/
chemokines/receptors, are largely deleterious. However, release
of some substances, such as vascular endothelial growth factor
(VEGF) from native hepatocytes, Kupffer cells, monocytes and
hepatic stellate cells helps in permeabilization of endothelial
cells. Coupled with the activation of LSEC, transplanted cells are
able to penetrate the endothelial barrier and then integrate them-
selves into the liver parenchyma [56]. This part of the process
requires 16–20 h from cell delivery. However, cumulatively,
nearly 80–90% of all transplanted hepatocytes are destroyed
due to sinusoidal events, including lack of entry into sinusoids,
inadequate or no adhesion to sinusoidal endothelium, oxidative
stress, cytokine-mediated toxicity, etc. Therefore, considerable
efforts have been devoted to understanding how these dele-
terious processes could be harnessed and thus yield drug-based
approaches for improving cell therapy outcomes.
The next process in transplanted cell engraftment concerns
integration of transplanted cells in the liver parenchyma. ThisS162 Journal of Hepatology 2015requires reconstitution over 1–5 days of plasma membrane struc-
tures and physical joining together of transplanted and native
hepatocytes [56]. Evidence of this process in rats include re-
associated gap junctions and bile canalicular networks with com-
ponents from both native and transplanted hepatocytes [25], as
noted above. Despite delays in the integration of transplanted
hepatocytes, it should be noteworthy that transplanted cells con-
tinue to express the normal repertoire of genes without interrup-
tions. However, it has been shown in rodents that hepatic gene
expression in transplanted cells is better supported in the hepatic
microenvironment compared with that in the spleen, which in
turn is superior to that in the peritoneal cavity [60]. The process
of transplanted cell integration in liver is aided by the activation
of stellate cells, which release matrix metalloproteinases and tis-
sue inhibitors of metalloproteinases to coordinate disruptions
and restitutions of the extracellular matrix during the entry and
resettling of transplanted cells [61]. After transplanted cells
become integrated in the liver parenchyma, gene expression pro-
ﬁles are driven by their position in the liver lobule, which is simi-
lar to adjacent native hepatocytes, and is under position-speciﬁc
regulation [29]. Moreover, transplanted cells exhibit normal pat-
terns of proliferative activity, i.e., no proliferation in the healthy
liver, and graded proliferation in response to injury in the liver
lobule that spares them, which is similar to the responses in adja-
cent healthy cells. In these approaches, transplanted cells are
noted to life-long survival in rodents [28].
In recent years, novel targets have been deﬁned to improve
engraftment of transplanted cells at these stages and several
drug-based strategies have been developed in preclinical models
that are potentially clinically relevant for enhancing cell engraft-
ment in the liver (Table 3). The major concepts have concerned
use of drugs to treat subjects prior to cell transplantation, such
that vascular or inﬂammatory changes induced by cell trans-
plantation are abolished or minimized, the endothelial barrier
interposed between liver sinusoids and parenchyma is disrupted,
or hepatic stellate cells are induced to release beneﬁcial sub-
stances, e.g., VEGF [58,59,62,63]. Similarly, novel concepts have
been developed in rodents where donor cells may be modiﬁed
prior to transplantation, e.g., by addition of extracellular matrix
components for better endothelial adhesion or incubation with
drugs to block endothelin (ET)-1 receptors, which otherwise
may transduce deleterious intracellular signals to activate
NF-jB-mediated cell death [63,64]. Of note, prior treatment of
recipients with anti-inﬂammatory drugs, e.g., the TNF-a blocker,
etanercept, had remarkable effects in rat by preventing dele-
terious cytokine/chemokine/receptor responses, leading to
improvements in transplanted cell survival and engraftment in
the liver [65]. The possibility of combining these approaches
has also been and is being examined for further beneﬁcial effects.
To this effect, the initial losses of transplanted cells may be miti-
gated by relatively straightforward approaches using available
drugs, which should aid future cell therapy applications.
The in vivo monitoring of delivered cells in patients is surpris-
ingly challenging. Whilst cells can be genetically labelled with
ﬂuorescent or other probes in animal models, cell tracking in
humans requires alternative methods. For short-term tracking of
transplanted cells, radiolabeling methods have been effective,
e.g., Indium-111- or 99m-technetium-labelled cells, in animals
as well as in people [32,66–68]. These methods are particularly
suitable for tracking the initial distribution and redistribution of
transplanted cells in various vascular beds. An example of thisvol. 62 j S157–S169
Table 3. Drug-based approaches for improving transplanted cell engraftment
and proliferation.
A. Pre-treatment of recipients prior to cell transplantation
Alteration of hepatic vascular responses
• ET-1 receptor blockade (bosentan, darusentan)
• Nitroglycerine
• Prostacyclin
Blockade of inflammatory cytokines/chemokines/receptors
• Etanercept
• Thalidomide
Disruption of hepatic endothelial barrier
• Cyclophosphamide
• Doxorubicin
• Rifampicin/phenytoin 
Activation of hepatic stellate cells
• Naproxen
• Celecoxib
B. Pre-treatment of donor cells prior to transplantation
• Extracellular matrix coating with adhesion factors or 
engineered molecules
• Dual ET-1 A and B receptor blockade (bosentan)
C. Combined preconditioning of recipients and of donor 
cells prior to or after cell transplantation
• Various combinations of drug regimens
• Thyroid hormone treatments
• Inhibitors of fumarylacetoacetate hydroxylase activity
• Other drugs promoting liver regeneration or cell survival 
under study
Table 4. Different types of potential cell therapy depending upon disease scenario.
Cell type Potential indication Clinical use? Advantag
Hepatocytes • Metabolic liver 
disease
• Paediatric liver 
failure
Yes • In routin
• Key me
cell
MSCs • Liver cirrhosis
• Liver failure
• Immune mediated 
liver disease
Some clinical 
reports and 
small number of 
randomised trials
• Easy to
• Genera
• May be
types to
EPCs • Liver cirrhosis No • Appear
regener
Macrophages • Liver cirrhosis No • Multiple
and reg
• Stimulat
to ampl
Embryonic stem 
cells (ESCs)
• Metabolic liver 
disease
• Liver failure
No • May be
populat
• Availab
compat
Induced 
pluripotent stem 
cells (IPSCs)
• Metabolic liver 
disease
• Liver failure
No • May be
populat
• Autolog
this wou
modifica
disease
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intrapulmonary shunting of transplanted cells via portosystemic
collaterals. Moreover, transplanted cellsmay be localized in extra-
hepatic sites by imaging of hepatic receptor function, e.g., asialo-
glycoprotein receptor as has been shown inmice and rats [69]. For
longer-term tracking of transplanted cells, molecular imaging
methods have also been developed. One such approach developed
in rodents and non-human primates used genetic constructs (her-
pes simplex virus thymidine kinase) for metabolizing ganciclovir
substrates for PET imaging [70]. Another approach tested in rats
utilised the imaging of natural ligands, e.g., radiocopper probes,
to demonstrate restoration of biliary copper excretion after trans-
plantation of healthy hepatocytes [71]. Furthermore, genetic
reporters capable of identifying unique alleles, including HLA-
speciﬁc alleles short tandem repeats, have been proposed as addi-
tional molecular methods to establish organ chimerism with
transplanted cells in mice [72]. Nonetheless, further clinically
applicable methods are needed for tracking transplanted cells
and monitoring their function in humans.
Inducing proliferation in transplanted cells for liver
repopulation
Despite the integration and indeﬁnite persistence of transplanted
cells in the absence of allograft rejection, more needs to be
learned about ways to induce proliferation in transplanted cells.
Although repeated transplantation of cells in large numbers cou-
pled with ways to decrease losses of transplanted cells could sub-
stantially increase delivery of cells to the liver [65], replacing
large amounts of the liver parenchyma with transplanted cells
is of enormous interest for many conditions. The fundamental
principle driving this area was gained from studies in animalses Disadvantages Reference
e clinical use
tabolic and synthetic 
• Shortage of supply 
• Engraftment in damaged 
liver problematic
• Susceptible to infection with 
hepatitis viruses
 isolate and expand
lly immune tolerising
 used with other cell 
 reduce inflammation
• Some clinical studies have 
been negative
• Poorly defined cell type
[50, 111]
 anti-fibrotic and pro-
ative
• Isolation and clinical use 
unclear
[47]
 effects on fibrosis 
eneration
e host macrophages 
ify the response
• Transient liver engraftment
• May be pro-fibrotic in 
certain circumstances
[44, 45]
 infinitely expandable 
ion of cells
le from GMP 
ible sources
• Ethics of use has been
questioned
• Long-term stability unclear
[93]
 infinitely expandable 
ion of cells
ous use is possible, 
ld require gene 
tion for genetic 
s
• Question over 
completeness of 
functionality
• Long-term stability as yet 
unproven
[102]
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B
Fig. 4. Proliferation of transplanted cells in the liver of healthy Dpp4
knockout mice. (A) Control animal subjected to no hepatic preconditioning
showing occasional transplanted cells with Dpp4 activity (red color, arrows) after
2 months. (B) Preconditioning of animals with rifampicin, phenytoin and
monocrotaline followed by hepatocyte transplantation showed extensive liver
repopulation to approximately 50% after 2 months.
Reviewwith progressive liver injury that spared healthy transplanted
hepatocytes. For instance, in alb-uPA transgenic mice, trans-
plantation of healthy hepatocytes resulted in progressive liver
repopulation [18]. Similarly, in FAH/ mice with progressive
liver injury, transplanted healthy hepatocytes or hepatocytes
derived as fusion products with components from extrahepatic
sources, such as donor bone marrow-derived mononuclear cells,
proliferated with progressive liver repopulation [73]. In LEC rats
modelling Wilson’s disease, extensive liver repopulation was
observed when healthy hepatocytes were transplanted [17].
Furthermore, induced injuries that constituted hepatic pre-
conditioning were successful in promoting proliferation of trans-
planted cells in rodents [18]. For instance, DNA-adduct forming
pyrollizidine alkaloids, retrorsine and monocrotaline, were found
to be effective in combination with additional injuries, such as
partial hepatectomy, carbon tetrachloride, or other drugs,
for inducing liver repopulation by transplanted cells.
Preconditioning of the liver with radiation plus partial hep-
atectomy, ischemia-reperfusion or toxic bile salts has also been
effective for liver repopulation. This included replacement of
mouse liver with transplanted hepatocytes as well as LSECs
[13,74]. However, these manipulations are not well-suited to
clinical applications and more conceptual development is neces-
sary, especially in regards to suitable drugs. Some progress has
been made in this area and further progress is anticipated (Fig. 4).
An alternative approach is to alter the proliferation of trans-
planted cells by inactivation of cell cycle suppressors, which
accelerated liver repopulation kinetics with transplanted hep-
atocytes in FAH/mice [19]. However, this approach is not with-
out cancer-risk. More recently, regulation of liver growth control
by the Hippo signalling pathway has come to attention [75]
which may provide additional targets to promote transplanted
cell proliferation.
It may be that hepatic preconditioning to replace LSECs will be
simpler than the replacement of hepatocytes because suitable
endothelial injury could possibly be achieved by ischemia-
reperfusion injury or other available drugs. Although this needs
further study this would be of beneﬁt for haemophilia A targeted
cell therapy.S164 Journal of Hepatology 2015Obtaining sufﬁcient hepatocytes in the clinic therapy
Human adult hepatocytes
Human hepatocytes are isolated from donor organ livers that are
either unused surplus or are rejected for transplantation in peo-
ple. Cells are typically isolated by using collagenase perfusion
techniques under clinical Good Manufacturing Practice (cGMP)
conditions [76]. The shortage of good-quality donor organs has
led to the use of marginal donors or segment IV/caudate lobes
when the donor liver is split for transplantation into more than
one recipient [77,78]. Progress is being made in understanding
molecular mechanisms underpinning the difﬁculty in isolating
viable hepatocytes from non-heart-beating cadaveric donors
[79]. Progress is also being made to improve the viability and
metabolic function of hepatocytes isolated from steatotic livers,
e.g., by the addition of N-acetylcysteine as an antioxidant to the
perfusion solution [80]. Given the increasing rates of obesity
and thus the frequency of fatty organs that are offered for trans-
plantation this area of research is of major importance for the
future. Isolated human hepatocytes may be transplanted freshly
after isolation or after cryopreservation even several years later
if stored appropriately, depending on regulatory practices [81].
However, the cell yield after thawing is low and the freezing pro-
cess also has a detrimental effect on the metabolic function and
cell attachment properties [82]. Therefore, an optimised protocol
may provide signiﬁcant improvements in cryopreserved cells but
further reﬁnements in the processes of cryopreservation and
mechanisms capable of preserving or enhancing cell viability
are required [83].Alternative sources of hepatocyte-like cells
Fetal hepatocytes
Clinical studies using fetal hepatocytes have suggested they are a
potentially useful source of cells for clinical therapy [35,36].
Understanding their behaviour in the host liver will help to deﬁne
conditions for their optimal usage. Interestingly, in the rat, fetal
hepatocytes have been shown to proliferate within the host liver,
even in the absence of the usual mitogenic stimulus required for
transplanted adult hepatocytes [84]. An interesting feature of this
was that the transplanted cells could induce apoptosis in the
recipient’s nearby host cells and thereby have a form of selective
advantage over the recipient liver cells. Although the proliferative
capacity of the rat fetal cells is encouraging, other studies utiliz-
ing human fetal cells have found different results. Haridass et al.
compared human fetal hepatocytes to adult hepatocytes in an
immunodeﬁcient mouse transplantation model. In this system
the fetal cells had less repopulation capacity on a cell per cell
basis than the adult hepatocytes [85]. Intriguingly, a recent study
has suggested that rat fetal hepatocytes may have anti-ﬁbrotic
properties when transplanted into damaged livers, which would
have the dual beneﬁt of supporting parenchymal regeneration
whilst targeting the scarring component of chronic liver disease
[86]. Whether this ﬁnding is a general phenomenon, seen using
human fetal hepatocytes, particularly in the setting of chronic
liver injury where there is signiﬁcant scarring is unknown.
Whether fetal cells could be less immunogenic compared with
adult hepatocytes is also unresolved at present. One issue invol. 62 j S157–S169
JOURNAL OF HEPATOLOGY
transferring these interesting preclinical studies ﬁndings into
clinical therapy is the issue of ethically sourcing sufﬁcient human
fetal hepatocytes for therapy in people. This aspect will likely
prevent fetal hepatocytes becoming a widely used clinical
resource, however the positive features of the cells may be used
to guide and inﬂuence the production of stem cell derived hep-
atocytes in the future.Hepatic progenitor cells (HPCs)
Whilst the normal human liver can regenerate efﬁciently through
hepatocyte division during severe or chronic liver disease the
regenerative capacity of hepatocytes is compromised. Under
these circumstances it has been thought that there are endoge-
nous HPCs that are activated and due to their bipotential nature
are able to regenerate both biliary epithelia and hepatocytes [87].
Recently this understanding has been challenged by studies in
mouse which suggest hepatocytes supply all the regenerative
capacity of the parenchyma, and the ductular reactions seen in
chronic injury do not regenerate parenchyma. Furthermore some
of the ductular reactions may arise from the de-differentiation of
mature hepatocytes during injury [88,89]. However recent data
using developmental ablation of foxl1 marked HPCs in mice sug-
gested that HPCs were a signiﬁcant source of parenchymal
regeneration and ablation of these foxl1 HPCs had a detrimental
effect upon the recovery from liver injury [90]. Further studies
are awaited in this area with conditional ablation of such cell
types to further delineate their regenerative role of such HPCs.
An important unresolved question is whether such studies in
mice are directly translatable to human liver disease. The injury
models used are often relatively mild and short lived compared
to the severe liver injury that occurs sometimes over decades in
humans and results in the signiﬁcant impairment of hepatocyte
proliferation. This controversial area is beyond the scope of this
review but is relevant for the question of whether an expandable
source of cells with hepatocyte or biliary potential could be
derived for cell therapy [91]. Lgr5 has been shown in mouse to
identify cells with a HPC characteristic. These Lgr5+ cells could
be grown into organoids with a high clonogenic capacity [46].
When such organoids were used in the FAH/ mouse they could
engraft within the parenchyma and provide nodules of function-
ing parenchyma. Furthermore, organoids have been derived from
human livers using EpCAM selection of bipotential hepatic
epithelial cells that originated in the ductal areas of the liver
[92]. Importantly these cells retained chromosomal stability dur-
ing prolonged culture. In order to translate these interesting ﬁnd-
ings into a clinical therapy a GMP compatible method of organoid
culture will be required; furthermore the engraftment and repop-
ulation characteristics of the organoids or cells derived from
these organoids will need to be deﬁned.Pluripotent sources of hepatocytes: Embryonic stem (ES) cells
and induced pluripotent stem cells (iPSCs)
ES cells are pluripotent stem cells derived from the inner cell
mass of a blastocyst. In humans this stage is reached at 4–5 days
post fertilization and consists of approximately 50–150 cells.
Because the derivation of ES cells requires destruction of the blas-
tocyst there is an inescapable moral dimension to their use. ESJournal of Hepatology 2015cells have been studied for a considerable time and human ES
cells have been derived at GMP level which would be required
for clinical use. Protocols have been developed to differentiate
ES cells sequentially into a hepatocyte-like cell (HLC) phenotype.
These have largely been based upon the signals that arise during
development including Activin A and Wnt 3A to encourage endo-
derm differentiation [93,94], bone morphogenic protein (BMP)
and ﬁbroblast growth factor (FGF) to aid hepatocyte differentia-
tion and then oncostatin M and dexamethasone to promote
maturity [95]. Further attempts have been made to enhance their
phenotype and stability using synthetic and natural cell matrices
[96], however despite this the pluripotent (ES cells and iPSCs-see
later) derived HLCs have a phenotype more in keeping with a
fetal than an adult hepatocyte phenotype [97]. However, in vivo
it is possible that more mature cells may develop. A recent study
demonstrated that pluripotent derived human HLCs can support
HCV infection and replication in vivo [98]. If the signals and fac-
tors present in vivo can be recapitulated in vitro it is possible that
more mature HLCs may be produced. 3D culture systems have
been tested and aid the increased maturity of the HLCs [99].
Because of the source and derivation of ES cells it is unlikely that
ES cell-derived HLCs would be routinely fully immunologically
matched to the recipient (blood antigen, tissue type and HLA).
Therefore, like whole liver transplantation, focusing upon blood
antigen matching would be one solution with the resulting need
for some immunosuppression.
iPSCs are pluripotent cells that can be reprogrammed from
adult cells using so-called pluripotency factors [100]. They have
the ethical advantage of not requiring embryonic material and
have the potential clinical advantage that they can be developed
from autologous starting cells, thereby obviating the requirement
for immunosuppression. Obviously if iPSCs were to be used for
the derivation of HLCs for the treatment of a genetic liver disease
then the autologous source would mean some form of ‘‘gene sur-
gery’’ would be required prior to use. Such an approach has been
adopted in a preclinical model of alpha-1-antitrypsin deﬁciency
[101].
Human HLCs can be efﬁciently derived from iPSCs [102], how-
ever using standard differentiation methods they are currently
more fetal in their phenotype than adult primary hepatocytes
[97]. The 3D culture of iPSCs has recently been shown to increase
their maturity closer to that of mature hepatocytes emphasizing
the need for an appropriate developmental niche for the cells
[103]. An exciting development was the demonstration that
when human iPSCs were cultured with endothelial and mes-
enchymal cells they self-formed in vitro into small liver organoids
that could be transplanted and had metabolic and synthetic func-
tion [104]. For clinical translation of these ﬁndings a way to grow
scalable organoids with appropriate 3D structure, vascularity and
ideally immune cell function would be required. Alternative
approaches have been taken to increase the maturity of human
iPSC derived hepatocytes. Kondo et al. used Activin A, dimethyl
sulfoxide, hepatocyte growth factor, oncostatin M, and
dexamethasone to induce hepatocyte maturity including drug
metabolism activity [105].
The use of pluripotent stem cell derived and directly repro-
grammed HLCs have several factors that would inﬂuence their
potential clinical use. Cells would need to be phenotypically
stable over a long period if they were to be transplanted into
the liver. This is particularly obvious in the setting of paediatric
cell therapy where decades of safety would be required fromvol. 62 j S157–S169 S165
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the transplanted cell. The HLC would need to be homeostatic and
respond to growth and renewal requirements in an appropriate
manner. Furthermore this capacity for appropriate proliferation
would be tested in the setting of chronic liver injury where there
are multiple and chronic signals acting to perturb the HLCs phe-
notype and physiological function. A particular concern when
contemplating the use of pluripotent cells as a source of HLCs
is the development of tumours although safety measures can
be envisaged such as physical encapsulation of the cells or the
use of an inbuilt suicide gene that could be activated in the situa-
tion of unwanted proliferation of the transplanted cells.Direct reprogrammed cells
A recent technological advance is the direct reprogramming of
human ﬁbroblasts into so-called induced hepatocytes (iHeps).
Sekiya and Suzuki showed that two transcription factors-
Hnf4alpha plus Foxa1, Foxa2 or Foxa3 could convert mouse adult
ﬁbroblasts into iHeps in vitro and could rescue the FAH/ mouse
[106]. In a similar approach ﬁbroblasts were converted to iHeps
by the transduction of Gata4, Hnf1alpha and Foxa3 and the inac-
tivation of p19. Furthermore, the iHeps showed good phenotypic
qualities and could repopulate the livers of Fah/Rag2/ mice,
rescuing a proportion of recipients [107].
Human induced hepatocytes (hiHeps) have been developed by
similar techniques to that seen in mouse. Huang et al. found that
the expression of HNF4, HNF1A, and FOXA3 in ﬁbroblasts allows
the production of hiHeps at a conversion rate approaching 20%
[108]. The paper by Du et al. used a more comprehensive set of
factors: C-MYC, HNF1A, HNF4A, HNF6, ATF5, PROX1, CEBPA,
and p53 shRNA to efﬁciently produce hiHeps [109]. Both sets of
hiHeps had similar gene expression proﬁles to mature human
hepatocytes but by no means identical. Encouragingly the
hiHeps also showed good in vivo functionality in a number of
mouse models of liver injury including the FRG (Fah//Rag2/
/Il2rg/) mouse.
A further reﬁnement of this technique has been employed in
mice whereby ﬁbroblasts are ﬁrst differentiated into induced
multipotent progenitor cells (iMPCs) [110]. These iMPCs could
be signiﬁcantly passaged and expanded then differentiated
through an endoderm stage to differentiated HLCs (so-called
iMPC-Heps). These iMPC-Heps could partially repopulate the
FAH/ mouse liver although again the resulting hepatocytic
function was short of that seen with primary hepatocytes.
Overall the use of pluripotent stem cells and directly repro-
grammed hepatocytes is in its infancy and whilst we must
applaud the advances made, we must also acknowledge the lim-
itations and problems associated with these cells. To date the
pluripotent derived cells are lacking sufﬁcient maturity for wide-
spread clinical use. Alongside this lack of maturity goes the con-
cern that the cells may be phenotypically unstable in vivo over a
prolonged period and when exposed to the ‘‘adverse niche’’ of the
damaged liver. Understanding and where possible recapitulating
the conditions of the developing human liver are likely to bring
advances in the maturity and stability of these pluripotent
derived cells. However, it is likely that understanding deeply
the complex epigenetic factors and the regulation of gene expres-
sion that evolve in forming hepatocytes will also be required to
produce hepatocytes that are ‘‘good enough’’ for clinical, and
even, routine clinical use – surely the eventual goal of this push
in the basic science area.S166 Journal of Hepatology 2015Conclusions and further perspectives
There is a clear requirement for an unlimited source of human
HLCs for transplantation with good function, phenotypic stability
and a near zero risk of tumorgenicity. Whilst easily stated this is a
demanding goal. Cells with a stem cell like potential that are
therefore able to give rise in a clonogenic manner to large num-
bers of progeny do carry a potential risk of unwanted and
unregulated cell growth. Such risks can be minimized by screen-
ing potential candidate cells in appropriate long-term studies in
animal models and by engineering in ‘‘safety devices’’ such as sui-
cide genes which would allow the killing of a cell upon
administration of a drug or small molecule. All risks of therapy
are relative to the disease in question and the transplantation
of a cell into an elderly person with a potentially fatal fulminant
liver disease is an entirely different risk proﬁle to the use of in a
baby where the transplanted cell may need to perform for dec-
ades without undergoing oncogenic change.
Stem cells have frequently been invoked as the future cell to
allow an almost limitless source of cells for therapy. However if
hepatocytes are the facultative stem cells of the liver then per-
haps it is time to re-examine the potential clonogenic capabilities
of the humble hepatocyte. Adult hepatocyte exhibits almost
unlimited clonogenicity in vivo yet in vitro has been very difﬁcult
to expand without the cells undergoing de-differentiation.
Understanding the in vivo cues which allow the homoeostatic
regulation of hepatocytes has progressed greatly. Hepatocytes
divide readily when required yet remain quiescent at other times
in the healthy liver. This in vivo understanding still needs to be
applied in vitro to human adult hepatocytes and allow division
without de-differentiation. Such knowledge would lead to the
ideal scenario of an inﬁnitely expandable cell source for clinical
cell therapy.Conﬂict of interest
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